THERAPY DOSSIER · th-c03d22b7f26a

Ticagrelor

Drug · Purinergic receptor P2Y12 negative allosteric modulator (NEGATIVE ALLOSTERIC MODULATOR)

No trauma translation Suggest a correction

Review required. This record is flagged as borderline.

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Purinergic receptor P2Y12 negative allosteric modulator (NEGATIVE ALLOSTERIC MODULATOR)
Target: CHEMBL2001
Injury models: Other
Reported indication: Acute coronary syndrome / reduction of thrombotic cardiovascular events (P2Y12 inhibitor; Brilinta, approved 2011)
First approval: 2010
Development stage: Approved for ACS (PLATO positive); black-box bleeding
ChEMBL record: CHEMBL398435 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: AR-C126532XX; AZD-6140; Brilinta; Brilique; Possia
Note: Not recorded

Clinical trials 6

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03476369 ↗PHASE4terminated

RCT of PCI patients receiving ticagrelor and fentanyl

Percutaneous Coronary Intervention

Enrolment: 45 · Results not recorded

NCT05643586 ↗PHASE4completed

Ticagrelor vs prasugrel on coronary microcirculation in elective PCI (PROMICRO-3)

Coronary Artery Disease

Enrolment: 50 · Results not recorded

NCT03381742 ↗PHASE2/PHASE3completed

Efficacy and safety of different ticagrelor regimens vs clopidogrel in CAD (SUPERIOR)

Coronary Artery Disease

Enrolment: 3043 · Results not recorded

NCT02531165 ↗NAcompleted

Fentanyl vs morphine analgesia on platelet inhibition after pre-hospital ticagrelor in STEMI

Acute Myocardial Infarction

Enrolment: 38 · Results not recorded

NCT02214654 ↗Phase not recordedunknown

Pilot study of ticagrelor to protect against type 2 diabetes-induced vascular damage

Type 2 Diabetes Mellitus · Stable Coronary Disease

Enrolment: 144 · Results not recorded

NCT04630288 ↗Phase not recordedunknown

Safety and efficacy of ticagrelor vs clopidogrel in acute coronary syndrome

Acute Coronary Syndromes

Enrolment: 1900 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28028070 ↗2016Reported benefit

Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.

MouseOtherC57BL/6Male

Model: Photochemical injury of the common carotid artery producing arterial thrombosis; complementary in vitro work used human aortic endothelial cells stimulated with tumour necrosis factor-alpha

Ticagrelor prolonged time to arterial occlusion compared with clopidogrel despite comparable antiplatelet effects, and reduced tissue factor expression in the endothelium of murine arteries. In human aortic endothelial cells ticagrelor, but not clopidogrel active metabolite, reduced TNF-alpha-induc…

Extraction: extract · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.

Loading the evidence…